Methods and compositions for protein delivery
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsDeb Chatterjee, Stanislaw Jan Kaczmarcyk
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for protein delivery. The invention features virus like particles, methods of making virus like particles and methods of using virus like particles to deliver proteins to a cell, to provide protein therapy and to treat diseases or disorders. The invention also features methods of targeting a protein to a cell, methods of protein therapy and methods of treating diseases or disorders using a TUS protein, a NLS or NES identified from full length TUS.
Claims19
A virus-like particle (VLP) comprising:
- a Gag fusion protein, wherein the Gag fusion protein comprises a matrix protein, a capsid protein, a nucleocapsid protein, covalently linked to a protein of interest selected from the group consisting of a cytotoxic enzyme, an interferon, a tumor suppressor, a recombinase, a hormone, and a stem cell transcription factor;
- and
- a fusogenic protein having reduced ligand-binding activity,
- wherein the Gag fusion protein does not comprise a reverse transcriptase, a protease, or an integrase.
VLP comprising:
- a first Gag fusion protein, wherein the first Gag fusion protein comprises a matrix protein, a capsid protein, a nucleocapsid protein, covalently linked to a protein of interest selected from the group consisting of a cytotoxic enzyme, an interferon, a tumor suppressor, a recombinase, a hormone, and a stem cell transcription factor;
- and wherein the first Gag fusion protein does not comprise a reverse transcriptase, a protease, or an integrase;
- a second Gag fusion protein, wherein the second Gag fusion protein comprises a protease;
- and a VSV-G glycoprotein.
A virus-like particle (VLP) comprising
- a Gag fusion protein, wherein the Gag fusion protein comprises a matrix protein, a capsid protein, a nucleocapsid protein, covalently linked to a protein of interest, and
- a fusogenic protein having reduced ligand-binding activity,
- wherein the protein of interest is selected from the group consisting of a cytotoxic enzyme, an interferon, a tumor suppressor, a protease, a recombinase, a hormone, and a stem cell transcription factor.
Dependencies are inferred from the claim text.